Department of Otolaryngology-Head and Neck Surgery, The Ohio State University Medical Center, Columbus, Ohio, USA.
Otolaryngol Head Neck Surg. 2012 Jan;146(1):68-73. doi: 10.1177/0194599811421298. Epub 2011 Aug 31.
To report long-term, health-related quality-of-life (HRQOL) outcomes in patients treated with transoral robotic surgery (TORS).
Prospective, longitudinal, clinical study on functional and HRQOL outcomes in TORS.
University tertiary care facility.
Patients who underwent TORS were asked to complete a Head and Neck Cancer Inventory before treatment and at 3 weeks and 3, 6, and 12 months postoperatively. Demographic, clinicopathological, and follow-up data were collected.
Sixty-four patients who underwent TORS were enrolled. A total of 113 TORS procedures were performed. The mean follow-up time was 16.3 ± 7.49 months. The HRQOL was assessed at 3 weeks and at 3, 6, and 12 months, with a response rate of 78%, 44%, 41%, and 28%, respectively. TORS was performed most frequently for squamous cell carcinoma (88%). There was a decrease from baseline in the speech, eating, aesthetic, social, and overall QOL domains immediately after treatment. At the 1-year follow-up, the HRQOL scores in the aesthetic, social, and overall QOL domains were in the high domain. Patients with malignant lesions had significantly lower postoperative HRQOL scores in the speech, eating, social, and overall QOL domains (P < .05). Patients who underwent adjuvant radiation therapy or chemotherapy and radiation therapy had lower postoperative scores in the eating, social, and overall QOL domains (P < .05).
The preliminary data show that patients who undergo TORS for malignancies and receive adjuvant therapy tend to have lower HRQOL outcomes. TORS is a promising, minimally invasive, endoscopic alternative surgical treatment of laryngopharyngeal tumors.
报告接受经口机器人手术(TORS)治疗的患者的长期健康相关生活质量(HRQOL)结果。
TORS 功能和 HRQOL 结果的前瞻性、纵向临床研究。
大学三级保健机构。
接受 TORS 的患者在治疗前和术后 3 周以及 3、6 和 12 个月时被要求完成头颈部癌症量表。收集人口统计学、临床病理学和随访数据。
共纳入 64 例接受 TORS 的患者,共进行 113 例 TORS 手术。平均随访时间为 16.3±7.49 个月。HRQOL 在 3 周和 3、6 和 12 个月时进行评估,相应的应答率分别为 78%、44%、41%和 28%。TORS 最常用于鳞状细胞癌(88%)。治疗后即刻,言语、进食、美学、社交和整体生活质量(QOL)领域的生活质量评分均较基线下降。在 1 年随访时,美学、社交和整体 QOL 领域的 HRQOL 评分处于较高水平。患有恶性病变的患者术后言语、进食、社交和整体 QOL 领域的 HRQOL 评分明显较低(P<.05)。接受辅助放疗或放化疗的患者术后进食、社交和整体 QOL 领域的评分较低(P<.05)。
初步数据表明,接受恶性肿瘤 TORS 治疗并接受辅助治疗的患者 HRQOL 结果较低。TORS 是一种有前途的微创内镜替代手术治疗咽喉肿瘤的方法。